Search
Filter Results
Displaying 601–610 of 898 results for “vision connection”
-
DiseaseMutations in CRB1 are a relatively common cause of several inherited retinal degenerations, including: Leber congenital amaurosis (LCA) retinitis pigmentosa (RP), and macular dystrophy (MD).
-
To make a bigger impact on our mission to turn early research into clinical trials for people with IRDs and dry AMD, the Foundation will grow its network of collaborators and partners.
-
Oct 11, 2024
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
Research NewsResearchers hope the molecule will slow the vision and hearing loss associated with USH3.
-
Sep 16, 2024
Foundation Fighting Blindness Hosts Chicago Night for Sight Event
Foundation NewsThe October 5th event will raise awareness and fund research driving treatments and cures for blinding diseases and macular degeneration.
-
Aug 14, 2024
Foundation NewsThe four-year study will inform clinical trial design for emerging USH3 therapies.
-
Jul 30, 2024
AREDS Formula Reduces Risk of Visual Acuity Loss for People with Geographic Atrophy
Research NewsPreviously, the formula was thought to only reduce risk of early age-related macular degeneration advancing to late-stage disease
-
Jul 26, 2024
Eye on the Cure Podcast | Episode 70: Karen Petrou
Eye on the CureKaren Petrou, the new board chair at the Foundation, talks to host Ben Shaberman about her vision for the Foundation moving forward. Karen has been an active director on the Foundation’s board for nearly two decades. She is co-founder and managing partner of Federal Financial Analytics, a firm providing analytical and advisory services on legislative, regulatory, and public-policy issues affecting financial services companies. Karen has RP and lives in Washington, DC, with her guide dog, Ike.
-
Jun 28, 2024
Eye on the Cure Podcast | Episode 68: Dr. Michael Telias
Eye on the CureFor this episode of Eye on the Cure, Michael Telias, PhD, an assistant professor at the University of Rochester in New York, talks with host Ben Shaberman about forthcoming clinical trials to evaluate the FDA-approved drug disulfiram (aka, Antabuse) for improving vision in people with retinitis pigmentosa and other retinal diseases. Disulfiram was originally developed to deter people from abusing alcohol.
-
May 16, 2024
Research NewsNo serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
Apr 25, 2024
Beacon StoriesWe’re honoring National DNA Day with the Danny family! When Sarah and A. J. found out their oldest daughter Lucia had Stargardt disease, it was a challenge to process her diagnosis. And then they realized their other five children could also be affected. Through genetic testing, they learned their five-year-old daughter Sarafina also has Stargardt disease. Now, Lucia and Sarafina have a bond like no other, and call each other the “Stargardt Sisters.”